CatalystFDA/Bio

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Zealand Pharma's Phase 3 ZUPREME program for petrelintide targets obesity, a major catalyst.

What changed

Zealand Pharma's Phase 3 ZUPREME program for petrelintide targets obesity, a major catalyst.

Why it matters

Zealand Pharma's Phase 3 ZUPREME program for petrelintide targets obesity, a major catalyst. — impact context not separately stored; see What changed.

Sources

eodhd